Ketamine

Generic Name
Ketamine
Brand Names
Ketalar
Drug Type
Small Molecule
Chemical Formula
C13H16ClNO
CAS Number
6740-88-1
Unique Ingredient Identifier
690G0D6V8H
Background

Ketamine is an NMDA receptor antagonist with a potent anesthetic effect. It was developed in 1963 as a replacement for phencyclidine (PCP) by Calvin Stevens at Parke Davis Laboratories. It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects. It was FDA approved in 1970, and from there, it has been used as an anesthetic for children or patients undergoing minor surgeries but mainly for veterinary purposes.

Indication

Ketamine is indicated as an anesthetic agent for recommended diagnostic and surgical procedures. If skeletal muscle relaxation is needed, it should be combined with a muscle relaxant. If the surgical procedure involves visceral pain, it should be supplemented with an agent that obtunds visceral pain. Ketamine can be used for induction of anesthesia prior other general anesthetic agents and as a supplement of low potency agents.

Reports have indicated a potential use of ketamine as a therapeutic tool for the management of depression when administered in lower doses. These reports have increased the interest for ketamine in this area and several clinical trials are launched for this indication.

Associated Conditions
-
Associated Therapies
General Anesthesia, Induction and Maintenance of General Anesthesia

Ketamine in Chronic Kid's (KiCK) Pain

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2012-12-24
Last Posted Date
2017-01-23
Lead Sponsor
Medical University of South Carolina
Target Recruit Count
7
Registration Number
NCT01755169
Locations
🇺🇸

Medical University of South Carolina, Charleston, South Carolina, United States

A Study To Examine The Effects Of PF-04958242 On Ketamine-Induced Cognitive Impairment In Healthy Volunteers

Phase 1
Completed
Conditions
Interventions
First Posted Date
2012-12-13
Last Posted Date
2019-11-21
Lead Sponsor
Biogen
Target Recruit Count
29
Registration Number
NCT01749098
Locations
🇺🇸

Pfizer Investigational Site, West Haven, Connecticut, United States

Developing Anesthesia as Post Traumatic Stress Disorder (PTSD) Therapy

First Posted Date
2012-11-29
Last Posted Date
2016-10-13
Lead Sponsor
Southern California Institute for Research and Education
Target Recruit Count
293
Registration Number
NCT01736020
Locations
🇺🇸

University of California, Irvine, Irvine, California, United States

Ketamine in Bariatric Surgery

Phase 3
Conditions
Interventions
First Posted Date
2012-11-12
Last Posted Date
2012-11-12
Lead Sponsor
University of Padova
Target Recruit Count
90
Registration Number
NCT01724983
Locations
🇮🇹

Azienda Ospedaliera, Padova, PD, Italy

Ketamine in the Treatment of Suicidal Depression

First Posted Date
2012-10-04
Last Posted Date
2020-03-11
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
82
Registration Number
NCT01700829
Locations
🇺🇸

Columbia University/New York State Psychiatric Institute, New York, New York, United States

PET Imaging of mGLuR5 With Drug Challenge

First Posted Date
2012-09-24
Last Posted Date
2017-04-21
Lead Sponsor
Yale University
Target Recruit Count
79
Registration Number
NCT01691092
Locations
🇺🇸

Connecticut Mental Health Center, New Haven, Connecticut, United States

🇺🇸

Yale University PET Center, New Haven, Connecticut, United States

🇺🇸

Yale University Magnetic Resonance Research Center (MRRC), New Haven, Connecticut, United States

Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2012-09-07
Last Posted Date
2016-02-29
Lead Sponsor
Mayo Clinic
Target Recruit Count
5
Registration Number
NCT01680172
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Yuma Regional Medical Center, Yuma, Arizona, United States

Study to Find the Dose of Rapidly Administered Ketamine for Brief Painful Procedures in Children

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2012-08-21
Last Posted Date
2019-04-25
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
111
Registration Number
NCT01669642
Locations
🇺🇸

St Louis Children's hospital, Washington university, Saint Louis, Missouri, United States

Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2012-08-17
Last Posted Date
2017-04-20
Lead Sponsor
Massachusetts General Hospital
Target Recruit Count
37
Registration Number
NCT01667926
Locations
🇺🇸

Depression Clinical and Reseach Program - MGH, Boston, Massachusetts, United States

Analgesic Effects of Topical Ketamine Mouthwash in Patients Receiving Chemoradiation or Radiotherapy for Head & Neck Cancer

Phase 2
Completed
Conditions
Interventions
First Posted Date
2012-07-31
Last Posted Date
2018-09-28
Lead Sponsor
Dartmouth-Hitchcock Medical Center
Target Recruit Count
11
Registration Number
NCT01653327
Locations
🇺🇸

Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, United States

© Copyright 2024. All Rights Reserved by MedPath